Descripción de la empresa
Aptevo Therapeutics Inc. operates as a clinical-stage research and development biotechnology company dedicated to advancing immunotherapeutic candidates for the treatment of various forms of cancer within the United States. The enterprise utilizes proprietary ADAPTIR and ADAPTIR-FLEX platforms to generate mono-specific antibodies, leveraging these technologies to address oncological challenges through a focused pipeline of investigational products. This organization functions within the Healthcare sector, specifically the Biotechnology industry, positioning it as a specialized entity focused on early-stage drug development rather than commercialized product sales. With a market capitalization of $4.93M and a workforce of 33 employees, the company maintains a lean operational structure typical of pre-revenue biotech firms where resources are heavily allocated toward research activities. The valuation metrics indicate that the market assigns a relatively small equity value to the company's future potential, reflecting the high-risk profile inherent in clinical-stage development where significant capital is required before achieving profitability or commercial revenue generation.
Salud financiera
The financial statements for Aptevo Therapeutics Inc. report N/A for revenue (TTM), reflecting the absence of commercial sales in its current operational phase. The company recorded a net income of $-25,967,000 and an EBITDA of $-26,072,000 for the trailing twelve months, highlighting substantial operational losses driven by research and development expenditures. The gap between revenue and net income reveals a cost structure dominated by burn rates associated with clinical trials and platform development, resulting in a profit margin of 0.0% alongside a gross margin of 0.0% and an operating margin of 0.0%. The free cash flow stands at $-15,881,000, which signifies a negative cash conversion rate that necessitates continuous external financing to sustain operations and fund future clinical milestones. Despite the negative earnings, the balance sheet holds $21.62M in cash against $4.63M in debt, providing a liquidity buffer that supports ongoing R&D efforts without immediate pressure to generate cash flow. The debt-to-equity ratio is recorded at 26.63, while the current ratio remains robust at 3.81, indicating that the company possesses ample short-term assets to cover its liabilities and maintain financial flexibility during the development phase. Return on Equity is -234.6% and Return on Assets is -76.9%, metrics that mathematically reflect the dilution of shareholder value and asset efficiency in the context of heavy investment in intangible clinical assets rather than profitable operations.
Evaluación de valoración
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -0.22, a negative figure that implies the market is pricing in future earnings that are currently projected to remain negative or undefined. The price-to-book ratio is 0.24, suggesting that the company's market capitalization is significantly below its book value, a common characteristic for early-stage biotechs where future intangible assets are not fully captured on the balance sheet. The price-to-sales ratio is N/A because there is no revenue to denominate against, and the EV/EBITDA stands at 0.46, an alternative metric that further underscores the lack of operational profitability and the reliance on asset lightness in its valuation model. The stock has demonstrated extreme volatility, trading between a 52-week high of $504.00 and a 52-week low of $3.83, illustrating the binary nature of biotech investment returns where small price movements can represent massive percentage changes. The current trading price relative to this range indicates a position far below the historical high, reflecting market skepticism regarding the probability of reaching commercialization milestones. The beta value of 1.51 indicates that the stock's price volatility is significantly higher than the broader market, meaning price swings are amplified by sector-specific news regarding clinical trial outcomes or regulatory approvals.
Growth & Income
The revenue growth year-over-year is N/A and the earnings growth year-over-year is N/A, as the company has not yet generated commercial sales to establish a growth trajectory. In the absence of positive earnings, there is no dividend yield or payout ratio to evaluate, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests all available resources and cash reserves directly into the expansion of its immunotherapeutic pipeline rather than distributing returns to shareholders. This growth profile is characterized by a complete reliance on capital markets for funding, with the 0.0% profit margin confirming that the business model is currently structured for capital appreciation through clinical success rather than income generation.